Evidence map›Paper›PMID 25820333›Full record

ArticleHaematologica2015

Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.

Massimiliano Bonifacio, Gianni Binotto, Elena Maino, Elisabetta Calistri, Luciana Marin, Luigi Scaffidi, Luca Frison, Federico De Marchi, Mauro Krampera, Giampiero Semenzato and 4 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Molecular monitoring in CML: how deep? How often? How should it influence therapy?Hematology. American Society of Hematology. Education Program · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Massimiliano BonifacioDepartment of Medicine, Section of Hematology, University of Verona, Italy massimiliano.bonifacio@univr.it.
Gianni BinottoPadua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy.
Elena MainoHematology Unit, Dell'Angelo Hospital, Venezia-Mestre, Italy.
Elisabetta CalistriHematology Unit, Ca' Foncello Hospital, Treviso, Italy.
Luciana MarinDivision of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy.
Luigi ScaffidiDepartment of Medicine, Section of Hematology, University of Verona, Italy.
Luca FrisonPadua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy.
Federico De MarchiDivision of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy.
Mauro KramperaDepartment of Medicine, Section of Hematology, University of Verona, Italy.
Giampiero SemenzatoPadua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy.
Renato FaninDivision of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy.
Achille AmbrosettiDepartment of Medicine, Section of Hematology, University of Verona, Italy.
Mario TiribelliDivision of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy.
Gruppo Triveneto LMC

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsChromosome AberrationsFusion Proteins, bcr-ablHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsRetrospective StudiesTime FactorsTreatment OutcomeAntineoplastic AgentsFusion Proteins, bcr-ablImatinib MesylateProtein Kinase Inhibitorsdiscordant responseimatinib-treated CML

Identifiers

PMID25820333
PMCPMC5004429

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.